[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note",
    "summary": "Bristol Myers Squibb (BMY) reachead $60.08 at the closing of the latest trading day, reflecting a +0.3% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=bbfdc19e9b3eda2c869ea56b38071ead81eb4efa7e037760f41e08a7f45dd17d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742420714,
      "headline": "Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note",
      "id": 133325483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb (BMY) reachead $60.08 at the closing of the latest trading day, reflecting a +0.3% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=bbfdc19e9b3eda2c869ea56b38071ead81eb4efa7e037760f41e08a7f45dd17d"
    }
  },
  {
    "ts": null,
    "headline": "Is Bristol-Myers Squibb (BMY) the Most Undervalued Biotech Stock to Invest In?",
    "summary": "We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other most undervalued biotech stocks to invest in. Trump’s Tariffs and the Pharma Sector On February 21, Jared Holz, Mizuho Securities […]",
    "url": "https://finnhub.io/api/news?id=248dbd66c61fc77a332039ff390cfc017d13c869da64ed52660dd702fd687a84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742394833,
      "headline": "Is Bristol-Myers Squibb (BMY) the Most Undervalued Biotech Stock to Invest In?",
      "id": 133325484,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other most undervalued biotech stocks to invest in. Trump’s Tariffs and the Pharma Sector On February 21, Jared Holz, Mizuho Securities […]",
      "url": "https://finnhub.io/api/news?id=248dbd66c61fc77a332039ff390cfc017d13c869da64ed52660dd702fd687a84"
    }
  },
  {
    "ts": null,
    "headline": "Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination",
    "summary": "Actinium Pharmaceuticals (ATNM) announced a clinical program comprising of trials studying Actimab-A in combination with either Keytruda – pembrolizumab -or Opdivo – nivolumab – which are blockbuster immunotherapies known as PD-1 inhibitors which are approved in multiple solid tumor indications. Keytruda, developed and commercialized by Merck (MRK) and Opdivo developed and commercialized by Bristol Myers Squibb (BMY), collectively generated $38.8B in sales in 2024 across several solid tumor canc",
    "url": "https://finnhub.io/api/news?id=9c073200cbeb7b0642f656dff7e5c20a16fe4344b3370ff66e4e87f269317ce6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742386292,
      "headline": "Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination",
      "id": 133324749,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Actinium Pharmaceuticals (ATNM) announced a clinical program comprising of trials studying Actimab-A in combination with either Keytruda – pembrolizumab -or Opdivo – nivolumab – which are blockbuster immunotherapies known as PD-1 inhibitors which are approved in multiple solid tumor indications. Keytruda, developed and commercialized by Merck (MRK) and Opdivo developed and commercialized by Bristol Myers Squibb (BMY), collectively generated $38.8B in sales in 2024 across several solid tumor canc",
      "url": "https://finnhub.io/api/news?id=9c073200cbeb7b0642f656dff7e5c20a16fe4344b3370ff66e4e87f269317ce6"
    }
  },
  {
    "ts": null,
    "headline": "10 Undervalued Dividend Growth Stocks: March 2025",
    "summary": "Read here for an analysis of top 10 undervalued dividend growth stocks yielding 4%+ with expert quality assessments and valuation insights.",
    "url": "https://finnhub.io/api/news?id=7d3209c952424595ff3eca0b0289d0228cfe59be6469dd1c4632b2e1a4fc4cec",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742374800,
      "headline": "10 Undervalued Dividend Growth Stocks: March 2025",
      "id": 133240018,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/181131486/image_181131486.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Read here for an analysis of top 10 undervalued dividend growth stocks yielding 4%+ with expert quality assessments and valuation insights.",
      "url": "https://finnhub.io/api/news?id=7d3209c952424595ff3eca0b0289d0228cfe59be6469dd1c4632b2e1a4fc4cec"
    }
  }
]